Clinical Trial Update: A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating Enzomenib (DSP-5336) for acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia, as well as mu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Multiple Myeloma
• Myelodysplastic Syndrome

Drugs mentioned

• Enzomenib (enzomenib)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute | Phase 1, Phase 2 | Status: RECRUITING